WuXi XDC and AbTis Partner to Advance ADC Development

• WuXi XDC has signed a Memorandum of Understanding (MOU) with AbTis to enhance antibody-drug conjugate (ADC) development through site-selective conjugation technology.

• The collaboration will integrate AbTis’ AbClick platform into WuXi XDC’s CRDMO services, expanding options for bioconjugation drug development.

WuXi XDC Cayman Inc., a global contract research, development, and manufacturing organisation (CRDMO) focused on bioconjugates, has entered into a strategic agreement with AbTis, a South Korea-based biotechnology company specialising in antibody-drug conjugates (ADCs). The Memorandum of Understanding (MOU) aims to advance ADC therapeutic development by integrating AbTis’ site-selective conjugation platform, AbClick, into WuXi XDC’s service portfolio.

The partnership will allow WuXi XDC to offer AbTis’ cutting-edge conjugation technology, which employs affinity peptide-assisted linkers for precise antibody-drug conjugation. By incorporating this technology, WuXi XDC seeks to expand its capabilities in bioconjugation drug development and provide broader solutions to its global clientele. Additionally, the collaboration opens pathways for AbTis to connect with WuXi XDC’s extensive client network, fostering new market opportunities.

WuXi XDC and AbTis share a commitment to accelerating innovation in bioconjugate drug manufacturing. Through this agreement, both companies aim to optimise Chemistry, Manufacturing, and Controls (CMC) platform capabilities, streamlining preclinical candidate selection and advancing next-generation ADCs. WuXi XDC’s all-in-one development and manufacturing platform will integrate AbTis’ technology to enhance drug development efficiency.

Dr. Jimmy Li, CEO of WuXi XDC, stated, “This collaboration with AbTis underscores our commitment to advancing innovation through strategic partnerships and creating meaningful value for our clients. With the addition of AbTis’ innovative conjugation technology into the WuXi XDC technology suite, it will provide our clients with broader options of advanced bioconjugation technologies and will tailor-made solutions to support the advancement of next-generation ADCs and bioconjugate drugs.”

With this collaboration, WuXi XDC and AbTis aim to drive ADC therapeutic innovation, supporting global clients in accelerating drug development timelines and delivering cutting-edge bioconjugate solutions to the market.